Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is United Laboratories International Holdings EV-to-FCF?
United Laboratories International HoldingsULIHF 80 EV-to-FCF is 12.47 as of Jul. 16, 2026, which is 2% above its 10-year median of 12.23. GuruFocus rates ULIHF with a GF Score™ of 80/100 and a GF Value™ of $1.43 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 563 Drug Manufacturers companies, United Laboratories International Holdings ranks better than 69.27% on this metric.
ULIHF's EV-to-FCF is ranked better than 69.27% of 563
companies
in the Drug Manufacturers industry
Industry Median: 21.03
vs ULIHF: 12.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
United Laboratories International Holdings (OTCPK:ULIHF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
United Laboratories International Holdings's PE Ratio (TTM) for today is calculated as:
United Laboratories International Holdings's share price for today is $1.24.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. United Laboratories International Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.154.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
United Laboratories International Holdings EV-to-FCF Related Terms
United Laboratories International Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings EV-to-FCF Chart
United Laboratories International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings EV-to-FCF vs Drug Manufacturers Industry
United Laboratories International Holdings's current Enterprise Value is $1,505 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. United Laboratories International Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $121 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (ULIHF) has a EV-to-FCF of 12.47 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on United Laboratories International Holdings and its competitors. This is near median its historical median of 12.23. Over the past decade, United Laboratories International Holdings' EV-to-FCF has ranged from 3.25 to 52.94. According to the industry distribution chart, United Laboratories International Holdings ranks #173 out of 563 companies in the Drug Manufacturers industry, placing it in the top 30.7%.
Is United Laboratories International Holdings' EV-to-FCF too high?
United Laboratories International Holdings' current EV-to-FCF of 12.47 is near median its 10-year median of 12.23. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 52.94. The Drug Manufacturers industry median EV-to-FCF is 21.03. United Laboratories International Holdings' value of 12.47 is 40.7% below this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #173 out of 563 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Laboratories International Holdings has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #173 out of 563 companies for EV-to-FCF. This puts United Laboratories International Holdings in the upper half of its industry. The industry median EV-to-FCF is 21.03. United Laboratories International Holdings' value of 12.47 is 40.7% below this benchmark. Historically, United Laboratories International Holdings' own EV-to-FCF has ranged from 3.25 to 52.94 over the past decade. While the company's 10-year median is 12.23 vs. the industry median of 21.03, United Laboratories International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.03, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current EV-to-FCF of 12.47 is 40.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current EV-to-FCF is 12.47, which is near median its own 10-year median of 12.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (ULIHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.43, compared to a current price of $1.24 — trading 13.3% below its estimated fair value. The current EV-to-FCF is 12.47, which is near median its 10-year median of 12.23 and 40.7% below the Drug Manufacturers industry median of 21.03. United Laboratories International Holdings' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For United Laboratories International Holdings (ULIHF), the current EV-to-FCF is 12.47 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (ULIHF) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be undervalued.
The current stock price of $1.24 is trading 13.3% below its estimated GF Value™ of $1.43.
GuruFocus considers United Laboratories International Holdings to be Modestly Undervalued.
Key valuation signals for ULIHF:
EV-to-FCF: 12.47 (near median its 10-year median of 12.23)
GF Value™: $1.43 vs. price of $1.24 (13.3% below fair value)
Industry Position: 40.7% below the Drug Manufacturers median (#173 of 563)
No single metric tells the full story. See the ULIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Business Description
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
80GF Score
Get the complete analysis for ULIHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ULIHF has been successfully added to your 
